Συγγραφείς:
Taher, A.T.
Karakas, Z.
Cassinerio, E.
Siritanaratkul, N.
Kattamis, A.
Maggio, A.
Rivella, S.
Hollaender, N.
Mahuzier, B.
Gadbaw, B.
Aydinok, Y.
Λέξεις-κλειδιά:
ferritin; growth differentiation factor 15; hepcidin; iron; ruxolitinib; transferrin; transferrin receptor; pyrazole derivative; ruxolitinib, anemia; beta thalassemia; clinical article; drug efficacy; drug withdrawal; erythrocyte transfusion; erythrocyte volume; erythropoiesis; ferritin blood level; fever; hemoglobin E-beta thalassemia; hormone blood level; human; iron blood level; iron metabolism; Letter; multicenter study; nuclear magnetic resonance imaging; open study; patient safety; phase 2 clinical trial; priority journal; protein blood level; spleen size; splenomegaly; staphylococcal bacteremia; thalassemia; toxic hepatitis; transferrin blood level; upper respiratory tract infection; virus pneumonia; beta thalassemia; erythroid cell; thalassemia, beta-Thalassemia; Erythroid Cells; Erythropoiesis; Humans; Pyrazoles; Thalassemia
